CONJUGATED ESTROGENS

Conjugated Estrogens Adverse Events Reported to the FDA Over Time

How are Conjugated Estrogens adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Conjugated Estrogens, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Conjugated Estrogens is flagged as the suspect drug causing the adverse event.

Most Common Conjugated Estrogens Adverse Events Reported to the FDA

What are the most common Conjugated Estrogens adverse events reported to the FDA?

Breast Cancer	95 (14.57%)
Breast Cancer Female	75 (11.5%)
Breast Cancer Metastatic	25 (3.83%)
Oestrogen Receptor Assay Positive	11 (1.69%)
Breast Cancer In Situ	9 (1.38%)
Condition Aggravated	9 (1.38%)
Dyspnoea	9 (1.38%)
Ovarian Cancer	9 (1.38%)
Progesterone Receptor Assay Positiv...	9 (1.38%)
Headache	8 (1.23%)
Major Depression	8 (1.23%)
	Show More
Chest Pain	7 (1.07%)
Drug Withdrawal Syndrome	7 (1.07%)
Heart Rate Increased	7 (1.07%)
Asthenia	6 (.92%)
Cerebrovascular Accident	6 (.92%)
Self Injurious Behaviour	6 (.92%)
Sleep Disorder	6 (.92%)
Thrombosis	6 (.92%)
Weight Increased	6 (.92%)
Abnormal Behaviour	5 (.77%)
Arthralgia	5 (.77%)
Cervix Carcinoma	5 (.77%)
Depression	5 (.77%)
Endometrial Sarcoma	5 (.77%)
Hot Flush	5 (.77%)
Mood Swings	5 (.77%)
Aggression	4 (.61%)
Fatigue	4 (.61%)
Myocardial Infarction	4 (.61%)
Pelvic Pain	4 (.61%)
Post Procedural Complication	4 (.61%)
Pyelonephritis	4 (.61%)
Urinary Tract Infection	4 (.61%)
Abdominal Pain Lower	3 (.46%)
Alopecia	3 (.46%)
Cerebrovascular Arteriovenous Malfo...	3 (.46%)
Dizziness	3 (.46%)
Hysterectomy	3 (.46%)
Irritability	3 (.46%)
Lymphoedema	3 (.46%)
Menorrhagia	3 (.46%)
Pain	3 (.46%)
Pain In Extremity	3 (.46%)
Postmenopausal Haemorrhage	3 (.46%)
Pulmonary Embolism	3 (.46%)
Retinal Haemorrhage	3 (.46%)
Suicidal Ideation	3 (.46%)
Thrombophlebitis Superficial	3 (.46%)
Venous Thrombosis Limb	3 (.46%)
Amenorrhoea	2 (.31%)
Anxiety	2 (.31%)
Blood Cholesterol Increased	2 (.31%)
Bone Density Decreased	2 (.31%)
Breast Cancer Recurrent	2 (.31%)
Cholecystitis	2 (.31%)
Coagulation Factor Viii Level Incre...	2 (.31%)
Confusional State	2 (.31%)
Contralateral Breast Cancer	2 (.31%)
Crying	2 (.31%)
Deep Vein Thrombosis	2 (.31%)
Dehydration	2 (.31%)
Drug Dependence	2 (.31%)
Drug Ineffective	2 (.31%)
Drug Interaction	2 (.31%)
Dry Skin	2 (.31%)
Endometrial Cancer	2 (.31%)
Endometrial Hyperplasia	2 (.31%)
Eye Haemorrhage	2 (.31%)
Flank Pain	2 (.31%)
Haemorrhage	2 (.31%)
Hepatitis	2 (.31%)
Iatrogenic Injury	2 (.31%)
Iliac Artery Thrombosis	2 (.31%)
Injury	2 (.31%)
Kidney Infection	2 (.31%)
Liver Function Test Abnormal	2 (.31%)
Nausea	2 (.31%)
Non-small Cell Lung Cancer	2 (.31%)
Procedural Complication	2 (.31%)
Pulmonary Artery Thrombosis	2 (.31%)
Subarachnoid Haemorrhage	2 (.31%)
Urticaria	2 (.31%)
Uterine Cancer	2 (.31%)
Vaginal Haemorrhage	2 (.31%)
Vena Cava Thrombosis	2 (.31%)
Weight Decreased	2 (.31%)
Abdominal Neoplasm	1 (.15%)
Acne	1 (.15%)
Agitation	1 (.15%)
Akathisia	1 (.15%)
Anaemia	1 (.15%)
Anaphylactic Shock	1 (.15%)
Aneurysm	1 (.15%)
Anger	1 (.15%)
Angina Unstable	1 (.15%)
Anorectal Operation	1 (.15%)
Appendicectomy	1 (.15%)
Arterial Occlusive Disease	1 (.15%)
Arthritis	1 (.15%)
Balance Disorder	1 (.15%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Conjugated Estrogens, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Conjugated Estrogens is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Conjugated Estrogens

What are the most common Conjugated Estrogens adverse events reported to the FDA?

Breast Neoplasms Malignant And Unsp...	208 (31.9%)
Reproductive Neoplasms Female Malig...	26 (3.99%)
Endocrine Investigations	20 (3.07%)
Embolism And Thrombosis	18 (2.76%)
Depressed Mood Disorders	13 (1.99%)
Neurological	13 (1.99%)
Therapeutic And Nontherapeutic Effe...	13 (1.99%)
Infections - Pathogen Unspecified	12 (1.84%)
Respiratory	10 (1.53%)
Suicidal And Self-injurious Behavio...	10 (1.53%)
Cardiac And Vascular Investigations	9 (1.38%)
	Show More
Epidermal And Dermal Conditions	9 (1.38%)
Headaches	9 (1.38%)
Procedural And Device Related Injur...	9 (1.38%)
Vascular	9 (1.38%)
Central Nervous System Vascular	8 (1.23%)
Mood Disorders	8 (1.23%)
Physical Examination Topics	8 (1.23%)
Coronary Artery	7 (1.07%)
Gastrointestinal Signs	7 (1.07%)
Joint	7 (1.07%)
Sleep Disorders	7 (1.07%)
Menstrual Cycle And Uterine Bleedin...	6 (.92%)
Musculoskeletal And Connective Tiss...	6 (.92%)
Reproductive Tract	6 (.92%)
Skin Appendage Conditions	6 (.92%)
Menopause And Related Conditions	5 (.77%)
Personality Disorders	5 (.77%)
Psychiatric And Behavioural Symptom...	5 (.77%)
Pulmonary Vascular	5 (.77%)
Hepatic And Hepatobiliary	4 (.61%)
Injuries	4 (.61%)
Mental Impairment	4 (.61%)
Psychiatric	4 (.61%)
Vulvovaginal Disorders	4 (.61%)
Anxiety Disorders	3 (.46%)
Cardiac And Vascular Disorders Cong...	3 (.46%)
Deliria	3 (.46%)
Electrolyte And Fluid Balance Condi...	3 (.46%)
Gallbladder	3 (.46%)
Gastrointestinal Motility And Defec...	3 (.46%)
Hematology Investigations	3 (.46%)
Lymphatic Vessel	3 (.46%)
Metastases	3 (.46%)
Obstetric And Gynecological Therape...	3 (.46%)
Respiratory And Mediastinal Neoplas...	3 (.46%)
Retina, Choroid And Vitreous Hemorr...	3 (.46%)
Uterine, Pelvic And Broad Ligament	3 (.46%)
Allergic Conditions	2 (.31%)
Angiedema And Urticaria	2 (.31%)
Arteriosclerosis, Stenosis, Vascula...	2 (.31%)
Breast	2 (.31%)
Breast Therapeutic Procedures	2 (.31%)
Cardiac Arrhythmias	2 (.31%)
Cardiac Disorder Signs	2 (.31%)
Gastrointestinal Therapeutic Proced...	2 (.31%)
Gastrointestinal Vascular Condition...	2 (.31%)
Hepatobiliary	2 (.31%)
Lipid Analyses	2 (.31%)
Movement Disorders	2 (.31%)
Muscle	2 (.31%)
Musculoskeletal And Soft Tissue Inv...	2 (.31%)
Ocular Hemorrhages And Vascular	2 (.31%)
Seizures	2 (.31%)
Vascular Hemorrhagic	2 (.31%)
Abdominal Hernias And Other Abdomin...	1 (.15%)
Age Related Factors	1 (.15%)
Anemias Nonhemolytic And Marrow Dep...	1 (.15%)
Aneurysms And Artery Dissections	1 (.15%)
Appetite And General Nutritional	1 (.15%)
Breast Neoplasms Benign	1 (.15%)
Bronchial Disorders	1 (.15%)
Connective Tissue Disorders	1 (.15%)
Eye	1 (.15%)
Family Issues	1 (.15%)
Fatal Outcomes	1 (.15%)
Gastrointestinal Hemorrhages	1 (.15%)
Gastrointestinal Inflammatory Condi...	1 (.15%)
Inner Ear And Viiith Cranial Nerve	1 (.15%)
Legal Issues	1 (.15%)
Lifestyle Issues	1 (.15%)
Manic And Bipolar Mood Disorders	1 (.15%)
Medication Errors	1 (.15%)
Metabolic, Nutritional And Blood Ga...	1 (.15%)
Miscellaneous And Site Unspecified ...	1 (.15%)
Oral Soft Tissue Conditions	1 (.15%)
Renal And Urinary Tract Neoplasms M...	1 (.15%)
Reproductive Neoplasms Female Benig...	1 (.15%)
Reproductive Organ And Breast Inves...	1 (.15%)
Schizophrenia And Other Psychotic	1 (.15%)
Skin Neoplasms Malignant And Unspec...	1 (.15%)
Spinal Cord And Nerve Root	1 (.15%)
Thyroid Gland	1 (.15%)
Tissue	1 (.15%)
Tongue Conditions	1 (.15%)
Upper Respiratory Tract Disorders	1 (.15%)
Urinary Tract Signs	1 (.15%)
Vascular Hypertensive	1 (.15%)
Viral Infectious	1 (.15%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Conjugated Estrogens, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Conjugated Estrogens is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.